[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT724456E - Anticorpos contra cd4 - Google Patents

Anticorpos contra cd4

Info

Publication number
PT724456E
PT724456E PT94927340T PT94927340T PT724456E PT 724456 E PT724456 E PT 724456E PT 94927340 T PT94927340 T PT 94927340T PT 94927340 T PT94927340 T PT 94927340T PT 724456 E PT724456 E PT 724456E
Authority
PT
Portugal
Prior art keywords
antibodies against
binding
ligand
monoclonal antibodies
specifically bind
Prior art date
Application number
PT94927340T
Other languages
English (en)
Inventor
Mark Alderson
Richard J Armitage
William C Fanslow Iii
Jodee Zappone
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of PT724456E publication Critical patent/PT724456E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT94927340T 1993-10-01 1994-09-02 Anticorpos contra cd4 PT724456E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01

Publications (1)

Publication Number Publication Date
PT724456E true PT724456E (pt) 2004-04-30

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94927340T PT724456E (pt) 1993-10-01 1994-09-02 Anticorpos contra cd4

Country Status (15)

Country Link
US (1) US5801227A (pt)
EP (1) EP0724456B1 (pt)
JP (1) JP3675819B2 (pt)
KR (1) KR960704576A (pt)
AT (1) ATE255906T1 (pt)
AU (1) AU686230B2 (pt)
CA (1) CA2172376C (pt)
DE (1) DE69433406T2 (pt)
DK (1) DK0724456T3 (pt)
ES (1) ES2211884T3 (pt)
FI (1) FI961285A (pt)
NO (1) NO961151D0 (pt)
NZ (1) NZ273504A (pt)
PT (1) PT724456E (pt)
WO (1) WO1995009653A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
KR19980702490A (ko) * 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
DK1082141T3 (da) * 1998-05-23 2005-12-05 Univ Leiden Medical Ct CD40-bindende molekyler og CTL-peptider til behandling af tumorer
AU4685900A (en) 1999-04-30 2000-11-17 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1975182A1 (en) 2000-02-01 2008-10-01 PanGenetics B.V. CD40-binding APC-activating molecules
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
DK1391464T3 (da) * 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
WO2003024480A2 (en) * 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20070098717A1 (en) * 2003-11-04 2007-05-03 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
RU2442606C2 (ru) * 2005-11-01 2012-02-20 Новартис Аг Применение анти-cd40-антител
CN101325970B (zh) * 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP3556774B1 (en) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anti-cd40 antibodies and uses thereof
JP6125489B2 (ja) 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
ES2879552T3 (es) 2012-10-30 2021-11-22 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
DK3303395T3 (da) 2015-05-29 2020-01-27 Abbvie Inc Anti-cd40-antistoffer og anvendelser deraf
KR20180044422A (ko) 2015-09-04 2018-05-02 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3026477A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
EP4393937A1 (en) 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
FI961285A0 (fi) 1996-03-20
CA2172376C (en) 2008-11-18
JP3675819B2 (ja) 2005-07-27
AU7681994A (en) 1995-05-01
WO1995009653A1 (en) 1995-04-13
EP0724456B1 (en) 2003-12-10
ES2211884T3 (es) 2004-07-16
NZ273504A (en) 1997-12-19
DE69433406D1 (de) 2004-01-22
DE69433406T2 (de) 2004-10-07
EP0724456A4 (en) 1997-07-02
ATE255906T1 (de) 2003-12-15
AU686230B2 (en) 1998-02-05
NO961151L (no) 1996-03-21
JPH09504169A (ja) 1997-04-28
US5801227A (en) 1998-09-01
CA2172376A1 (en) 1995-04-13
FI961285A (fi) 1996-03-20
DK0724456T3 (da) 2004-04-13
KR960704576A (ko) 1996-10-09
NO961151D0 (no) 1996-03-21
EP0724456A1 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
PT724456E (pt) Anticorpos contra cd4
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
DE60005953D1 (de) Stapelbare statische mischelemente
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE69128543D1 (de) Monoklonale antikörper der maus
MX347883B (es) Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
ATE296312T1 (de) Metalkomplexbildner
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
DK0854727T3 (da) Tumorafstødelsesantigener, der præsenteres af HLA-B44-molekyler, og anvendelser af samme
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk